PIA
FATE icon

Piedmont Investment Advisors’s Fate Therapeutics FATE Stock Holding History

Piedmont Investment Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-863
Closed -$10K – 1443
2018
Q2 		$10K Buy
+863
New +$9.51K ﹤0.01% 1830

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Piedmont Investment Advisors's FATE Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Fate Therapeutics (FATE) in Q3 2018, closing a stake of 863 shares — an estimated $10K sold.

Piedmont Investment Advisors first reported a position in FATE in Q2 2018 and held it in 1 quarter. The position peaked at $10K in Q2 2018. 116 funds tracked by Wall St. Rank hold FATE as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Fate Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 863 Fate Therapeutics shares in Q3 2018, an estimated $10K.
  • Piedmont Investment Advisors first reported a position in Fate Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Fate Therapeutics position peaked at $10K in Q2 2018.
  • 116 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.